Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis
San Mateo, California, September 13, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has completed enrollment of its Phase 2b…
Read More
Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)
San Mateo, California, August 4, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it will present additional Phase 2a data highlighting…
Read More
Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL’s International Liver Congress (ILC) 2022
San Mateo, California, June 8, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it…
Read More
Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022
Company Adopts Denifanstat as Non-Proprietary Name for TVB-2640 San Mateo, California, May 4, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty…
Read More
New Data from Sagimet’s Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640’s Positive Effect Across Patients with NASH in the U.S. and China
San Mateo, California, November 12, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will…
Read More
Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting 2021
FOR IMMEDIATE RELEASE San Mateo, California, October 4, 2021– Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results from its Phase 2 FASCINATE-1 trial of TVB-2640 in patients…
Read More
Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today…
Read More
Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat
San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology…
Read More
Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors
San Mateo, California, May 3, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of…
Read More
Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress™ 2021 (EASL)
San Mateo, California, April 23, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that additional clinical…
Read More
Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH) San Mateo, California, March 16, 2021 – Sagimet Biosciences Inc., a…
Read More
Sagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer
Dr. Martins Joins the Company to Help Advance Sagimet’s Pipeline of FASN Inhibitors San Mateo, California, March 11, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing…
Read More
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
– Oral FASN inhibitor ASC40 shown to meaningfully reduce liver fat with a 50% responder rate – Consistent improvement in biomarkers of liver inflammation as observed in U.S. cohort Shanghai,…
Read More
Sagimet Biosciences Raises $80 Million in Crossover Financing
Altium Capital, HM Capital, Invus, and PFM Health Sciences join previous investors Ascletis, Kleiner Perkins, New Enterprise Associates, Rock Springs Capital, and two undisclosed leading public equity healthcare investors in…
Read More
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
Shanghai, China and San Francisco, California, United States, November 19，2020 – Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced…
Read More
Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020
San Mateo, California, October 6, 2020 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 in nonalcoholic steatohepatitis (NASH)…
Read More
Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640
Oral FASN inhibitor TVB-2640 significantly reduces liver fat with a 61% responder rate Demonstrates improvement in markers of liver function and fibrosis Results to be presented on August 28 at…
Read More
Data on Sagimet’s Lead Candidate TVB-2640 to be Presented at EASL ILC 2020
Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology…
Read More
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways San Mateo, California, August 5, 2019 – 3-V Biosciences, a clinical-stage biotechnology company, announced today that…
Read More
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 – 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences…
Read More
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its…
Read More
3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®
Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class…
Read More
3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA
Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been…
Read More
3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA
Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference…
Read More
3-V Biosciences to Present Data at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna
Menlo Park, California, September 17, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from its ongoing Phase 1 clinical…
Read More
3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015
Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush…
Read More
3-V Biosciences Provides Clinical Update on TVB-2640 at AACR Metabolism and Cancer Conference
Menlo Park, California, June 9, 2015: 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, is pleased to announce that new…
Read More
3-V Biosciences Appoints Rekha Hemrajani as Chief Financial Officer
Menlo Park, California, February 19, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Rekha Hemrajani has…
Read More
3-V Biosciences Announces Closing of $28.5M Financing Round
Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the closing of its…
Read More
3-V Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
Menlo Park, California, December 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Chief Executive Officer,…
Read More
3-V Biosciences Announces Presentation of First Human Clinical Data for Lead Oral FASN Inhibitor Candidate at EORTC-NCI-AACR 2014
Barcelona, Spain, November 19, 2014. 3-V Biosciences, Inc., (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, today presented the first human clinical…
Read More
3-V Biosciences to Present Clinical and Preclinical Data for FASN Inhibitors at EORTC-NCI-AACR 2014
Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, will present clinical data for its…
Read More
3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB- 2640 in Patients with Advanced Solid Tumors First
FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease,…
Read More
3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch,…
Read More
3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics…
Read More
3-V Biosciences Completes $20 Million Series C Financing
Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series…
Read More
3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for…
Read More
3‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012
Menlo Park, California, October 1, 2012. 3‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the…
Read More
3‐V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Menlo Park, California, July 10, 2012. 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula…
Read More
3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program
Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the…
Read More
3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of…
Read More
3-V Biosciences Appoints Dr. George W.Kemble, PhD, as Chief Scientific Officer
Menlo Park, California, August 15, 2011. 3-V Biosciences, Inc. announced today the appointment of Dr. George W. Kemble, PhD as Chief Scientific Officer. “We are very pleased to have George…
Read More
3-V Biosciences Promotes Stephen R.Brady to Chief Business Officer
Menlo Park, California, February 10, 2011. 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer. “Steve's contributions have been pivotal as a member of…
Read More
3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Menlo Park, California, September 30, 2010. 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer. We are very pleased to have Merdad…
Read More
James F. Young joins 3-V Biosciences Board of Directors
Menlo Park, California, July 20, 2010. 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. “We are very pleased to welcome Jim…
Read More
3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer
Menlo Park, California, June 3, 2010. 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer. “Ed Connor is among the most experienced…
Read More
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
Menlo Park, California, May 13, 2010. 3-V Biosciences, Inc. announced today the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations, the consolidation of…
Read More